Last updated: October 23, 2026
TILADE is the former brand name for nedocromil sodium inhalation aerosol, a prophylactic asthma treatment developed by Fisons and later commercialized through the Rhône-Poulenc Rorer, Aventis, and Sanofi corporate lineage. Its commercial decline resulted from therapeutic substitution by inhaled corticosteroids, combination inhalers, and newer asthma biologics. TILADE is no longer a meaningful commercial product in the United States, and public filings do not report standalone product revenue.
What is TILADE and how was it used?
TILADE contains nedocromil sodium, a nonsteroidal anti-inflammatory agent used for the maintenance treatment of asthma. It was not indicated for rapid relief of acute bronchospasm. The historical U.S. product was an inhalation aerosol delivering 1.75 mg of nedocromil sodium per actuation.[1]
Nedocromil was positioned between older mast-cell stabilizers, such as cromolyn sodium, and inhaled corticosteroids. Its role was preventive rather than rescue-based.
| Attribute |
TILADE historical profile |
| Active ingredient |
Nedocromil sodium |
| Drug class |
Nonsteroidal anti-inflammatory asthma therapy |
| Dosage form |
Metered-dose inhalation aerosol |
| Historical U.S. strength |
1.75 mg per actuation |
| Primary use |
Maintenance treatment of asthma |
| Rescue therapy |
No |
| Original developer |
Fisons |
| Later corporate lineage |
Rhône-Poulenc Rorer, Aventis, Sanofi |
| U.S. regulatory application |
Historical NDA 19-789 records are associated with Tilade |
| Current U.S. commercial status |
No active commercial market |
| Biosimilar relevance |
None; TILADE is a small-molecule drug |
The product’s clinical position weakened as treatment guidelines increasingly favored inhaled corticosteroids for persistent asthma. Combination inhalers containing an inhaled corticosteroid and a long-acting beta agonist then displaced many older maintenance products.
When did TILADE lose exclusivity and when was it discontinued?
TILADE’s meaningful market exclusivity ended years before its commercial withdrawal. The relevant intellectual-property protection was associated with the original nedocromil compound, formulation, and inhaler technology. Those protections have expired.
The public record does not identify an active U.S. patent estate that currently blocks generic or alternative development. FDA records classify the historical product as discontinued, without identifying a safety or efficacy withdrawal as the reason for discontinuation.[2]
TILADE exclusivity timeline
| Period |
Event |
| 1970s-1980s |
Fisons develops nedocromil as a preventive asthma therapy |
| 1980s |
Nedocromil products enter selected international markets |
| Early 1990s |
U.S. approval and commercialization of Tilade inhalation aerosol |
| 1990s |
Rhône-Poulenc Rorer becomes associated with U.S. commercialization |
| Late 1990s-early 2000s |
Aventis inherits the product through corporate consolidation |
| 2000s |
Sanofi becomes the relevant successor company |
| By the late 2000s |
U.S. commercial availability ends or becomes inactive |
| Current position |
No meaningful marketed TILADE product in the United States |
Exact patent expiration dates are less commercially relevant than the fact that the product has been off-patent for many years. No current Orange Book patent listing appears to create a market-entry barrier for nedocromil sodium inhalation aerosol.
What is the FDA regulatory and Orange Book status of TILADE?
TILADE does not have a current commercial position comparable with an actively marketed FDA-approved asthma product. Historical FDA records identify the product and its NDA history, but the product is listed as discontinued rather than actively marketed.[2]
The FDA’s discontinued-product designation does not by itself establish a safety withdrawal. For TILADE, the commercial outcome is consistent with low demand, therapeutic substitution, and the economics of maintaining an older metered-dose inhaler.
Orange Book implications
The Orange Book is relevant because it records approved drug applications and listed patents for certain marketed products. TILADE’s historical approval does not create a current regulatory exclusivity position.
Key implications are:
- No active brand franchise supports a current Paragraph IV litigation strategy.
- No current Orange Book patent listing is known to block a generic filing.
- A new applicant would face development, manufacturing, and commercial hurdles rather than a major patent barrier.
- An applicant might need to address product-specific device performance, dose delivery, chemistry, manufacturing, and controls requirements.
A generic applicant could pursue an abbreviated pathway only if an appropriate reference product and regulatory route remained available. The practical difficulty is that a discontinued inhalation product may require more regulatory work than its expected sales can justify.
How many patents protect TILADE today?
No meaningful active patent estate protects TILADE today. Historical patents covering nedocromil, its pharmaceutical salts, inhalation formulations, and delivery systems have expired or have no apparent commercial effect.
The relevant protection historically fell into four categories:
- Composition-of-matter protection for nedocromil or related chemical forms.
- Pharmaceutical formulation patents.
- Metered-dose aerosol and propellant technologies.
- Manufacturing and process patents.
What formulations were protected?
The commercial product was an inhalation aerosol designed to deliver a consistent dose from a metered-dose inhaler. Historical formulation protection could have covered:
- Nedocromil sodium particle characteristics.
- Suspension or solution chemistry.
- Propellant systems.
- Valve and actuator performance.
- Dose uniformity.
- Container and device configuration.
- Manufacturing controls for inhalation-grade material.
Those protections do not provide a current barrier to competitors because the relevant patent terms have expired. A modern entrant would still need to demonstrate reliable dose delivery and product equivalence or establish a new drug application pathway.
Were there Paragraph IV challenges or patent lawsuits involving TILADE?
TILADE does not have an active U.S. Paragraph IV controversy. No material current patent litigation affects the product.
The absence of litigation reflects the product’s commercial status. Paragraph IV litigation generally requires an economically attractive branded market and a generic challenger seeking approval before patent expiration. TILADE no longer has the revenue base needed to support that model.
Publicly available information does not indicate a major modern settlement agreement between the TILADE brand holder and a generic challenger. Any historical patent disputes associated with nedocromil or inhaler technology do not appear to have a current impact on market access.
Generic launch scenarios
A generic TILADE launch would face three possible commercial outcomes:
| Scenario |
Commercial result |
| Direct generic launch |
Limited demand and weak reimbursement pull |
| Authorized or licensed relaunch |
Possible niche opportunity, but requires device and supply investment |
| Reformulated inhaler |
Potential regulatory differentiation, but higher development cost |
The most likely outcome is continued market absence rather than a conventional generic wave.
Which companies challenged or replaced TILADE?
No current company is publicly positioned as a direct TILADE challenger. Its competitive displacement came from therapeutic alternatives rather than a single generic competitor.
Main replacement classes
| Competitive class |
Examples |
Competitive advantage |
| Inhaled corticosteroids |
Beclomethasone, budesonide, fluticasone |
Stronger guideline position for persistent asthma |
| ICS/LABA combinations |
Fluticasone/salmeterol, budesonide/formoterol |
Maintenance and symptom-control benefits |
| Leukotriene modifiers |
Montelukast |
Oral administration and broader prescribing familiarity |
| Long-acting bronchodilators |
Various LABA products |
Improved maintenance bronchodilation when appropriately combined |
| Biologics |
Omalizumab, mepolizumab, benralizumab, dupilumab |
Targeted treatment for severe asthma phenotypes |
Nedocromil was disadvantaged by dosing frequency, limited market familiarity, and the availability of more effective or more convenient maintenance options.
What is the financial trajectory of TILADE?
TILADE’s financial trajectory was a progression from launch-stage specialty revenue to low-volume legacy-product economics and eventual withdrawal. Public company reports do not disclose a standalone TILADE revenue series.
The product’s revenue decline can be analyzed through commercial drivers rather than reported product-level figures:
- Loss of exclusivity reduced pricing power.
- Inhaled corticosteroids became the standard controller treatment.
- Combination inhalers captured maintenance-treatment demand.
- The product lacked a durable device or formulation moat.
- Low volume weakened manufacturing and distribution economics.
- The cost of maintaining an older inhaler platform exceeded likely revenue.
- Product discontinuation eliminated recurring brand revenue rather than transferring it to a high-value successor.
Financial trajectory by phase
| Phase |
Revenue profile |
Primary driver |
| Launch and early adoption |
Growth from initial asthma uptake |
Introduction of a nonsteroidal controller |
| Mature branded period |
Stable but pressured |
Physician adoption and competition from corticosteroids |
| Post-exclusivity period |
Declining |
Generic exposure and therapeutic substitution |
| Late commercial period |
Low and structurally weak |
Small patient base and declining prescribing |
| Current period |
No material TILADE revenue |
Product discontinuation |
TILADE was unlikely to have contributed material revenue to Sanofi’s consolidated results after the company’s portfolio shifted toward higher-value prescription medicines, vaccines, specialty care, and biologics. Sanofi’s public annual reports aggregate products and therapeutic areas at a level that does not isolate TILADE revenue.[3]
How strong is the TILADE patent estate?
The current patent estate is commercially weak to nonexistent. Patent strength should be separated into historical protection and present-day enforceability.
| Patent-estate factor |
Current assessment |
| Composition patent |
Expired |
| Formulation patent |
Expired or commercially inactive |
| Device patent |
Expired or not relevant to the historical product |
| Method-of-use patent |
No meaningful current barrier identified |
| Orange Book leverage |
None of material commercial significance |
| Paragraph IV leverage |
None |
| Manufacturing know-how |
Potentially relevant, but not a market-blocking right |
| Regulatory exclusivity |
Expired |
| Biosimilar protection |
Not applicable |
The remaining barriers are operational. A company would need inhalation manufacturing capability, analytical methods, device engineering, regulatory resources, and sufficient distribution economics. Those are real barriers, but they are not equivalent to enforceable patent exclusivity.
Does TILADE have biosimilar risk?
No. TILADE is a chemically synthesized small molecule, not a biologic. Biosimilar regulation does not apply.
Any future competitor would be a generic or follow-on inhalation product. The central regulatory issues would involve active-ingredient quality, delivered dose, aerodynamic particle-size distribution, device performance, and comparative product performance.
What licensing deals affected TILADE?
TILADE originated with Fisons, which developed and commercialized nedocromil before the company’s assets moved through larger pharmaceutical companies. Rhône-Poulenc Rorer, Aventis, and Sanofi became associated with the product through corporate succession and portfolio consolidation.
There is no current licensing arrangement that gives TILADE a meaningful commercial position. Public disclosures do not identify a recent licensing transaction that revived or monetized the product.
The key commercial transition was corporate ownership transfer, not an active modern licensing strategy. After the product’s market declined, the economic value of licensing the brand or legacy formulation became limited.
What generic entry risks exist for TILADE?
The principal risk is not a sudden generic launch against a high-revenue brand. The principal risk is that a low-cost manufacturer could reintroduce nedocromil or a comparable inhaled product if it identified an underserved niche.
That risk remains limited because:
- The historical brand has little current demand.
- Physicians have established alternatives.
- Asthma guidelines generally favor inhaled corticosteroid-based treatment.
- Inhaler development has higher complexity than oral solid-dose generic development.
- Payers may not provide favorable formulary positioning.
- The commercial market would be fragmented by stronger alternatives.
A relaunch would need to create a clinical or economic reason for prescribers to switch from established controller therapies.
How does TILADE compare with cromolyn and modern asthma therapies?
TILADE and cromolyn share a preventive, nonsteroidal mechanism category, but both have been displaced by inhaled corticosteroids and newer targeted therapies.
| Product class |
Current commercial position |
Relative position to TILADE |
| Cromolyn inhalation |
Limited and largely legacy |
Similar historical role, generally weaker market relevance |
| Nedocromil/TILADE |
Discontinued in the U.S. |
No current commercial franchise |
| Inhaled corticosteroids |
Established controller standard |
Stronger guideline and market position |
| ICS/LABA products |
Major maintenance category |
Greater convenience and clinical adoption |
| Biologics |
Premium severe-asthma segment |
Higher cost, targeted use, no direct product-level equivalence |
TILADE’s commercial decline was therefore driven by both patent expiry and clinical obsolescence.
What is the geographic status of TILADE?
The product’s availability has varied by jurisdiction, but TILADE no longer has a substantial global commercial footprint. Historical marketing occurred in the United States and other markets, including markets where nedocromil inhalers were sold under the Tilade name or related branding.
The market pattern was broadly similar across developed healthcare systems:
- Initial uptake in asthma maintenance therapy.
- Increasing competition from inhaled corticosteroids.
- Declining prescriptions after guideline and formulary changes.
- Discontinuation or loss of routine availability.
Country-specific registration status may differ because national agencies maintain separate product records. No major current market appears to support TILADE as a strategically important branded asthma product.
Key Takeaways
- TILADE is the former brand for nedocromil sodium inhalation aerosol.
- The product was a preventive asthma treatment, not a rescue inhaler.
- Its patent and regulatory exclusivity have expired.
- No current Orange Book patent position creates a meaningful market barrier.
- No active Paragraph IV dispute or material patent litigation affects TILADE.
- TILADE is not a biologic and has no biosimilar exposure.
- Public filings do not report standalone TILADE revenue.
- Revenue declined because of patent expiry, inhaled corticosteroid adoption, combination inhaler competition, and weak late-stage manufacturing economics.
- Any future entrant would face device, regulatory, manufacturing, and commercial barriers rather than strong patent barriers.
- The product is commercially obsolete in the United States and has no material current contribution to Sanofi’s financial results.
FAQs
Is TILADE still available in the United States?
No. TILADE is not a meaningful currently marketed U.S. asthma product. Historical FDA records classify the product as discontinued.
What drug replaced TILADE?
Inhaled corticosteroids and inhaled corticosteroid/long-acting beta agonist combinations replaced TILADE in routine asthma maintenance treatment. Severe asthma patients may receive biologic therapy based on disease phenotype.
Is nedocromil sodium generic?
Nedocromil sodium is an off-patent small molecule, but the historical inhaled product does not have a significant active U.S. generic market.
Did Sanofi report TILADE sales?
No standalone TILADE revenue is generally reported in Sanofi’s public financial statements. Any late-stage revenue would have been immaterial within the company’s consolidated results.
Can a company relaunch TILADE?
A company could potentially pursue a new regulatory and manufacturing strategy for nedocromil sodium, subject to applicable FDA requirements. The principal obstacles would be market demand, inhaler development, product testing, and commercial return, not an active patent monopoly.
References
- U.S. Food and Drug Administration. (1992). Tilade inhalation aerosol prescribing information.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs and discontinued product records for Tilade.
- Sanofi. (2007-2024). Annual reports and universal registration documents.
- Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
